Acadia Pharmaceuticals | ACAD - 股票



金融业
股票价格
USD
资产
USD 1.61B
现金及等价物
USD 851.46M
销售成本
USD 24.79M
流动资产
USD 1.1B
流动负债
USD 305.52M
债务
USD 52.19M
EBIT
USD -4.62M
EBITDA
USD 20.32M
员工
653
EPS每股收益
USD 0.02
股本和储备
USD 1.25B
销售毛利
USD 243.27M
债务利息支出
USD 0
利息收入
USD 8.33M
贷款资金
USD 0
市值
USD 3.56B
净收入
USD 3.64M
营业费用
USD 272.68M
营业利润
USD -4.62M
普通股股本
USD 169.18M
PE价格收益
10.08
税前利润
USD 3.98M
销售收入
USD 268.06M
销售和管理费用
USD 160.79M
股票
USD 31.57M
贸易债权人
USD 12.25M
应收帐款人
USD 148.38M


股票 更改 日
Acadia Pharmaceuticals USD 31.57M 3.1M 2026-03
ALKERMES USD 336.7M 140.08M 2026-03
Alnylam Pharmaceuticals USD 200.15M 117.43M 2026-03
Biogen USD 1.95B 219.1M 2026-03
BioMarin Pharmaceutical USD 1.27B 25.66M 2026-03
Bristol-Myers Squibb USD 2.76B 66M 2026-03
Cara Therapeutics USD 900K 0 2025-03
Corcept Therapeutics USD 12.89M 22K 2026-03
Eisai JPY 236.46B 9.14B 2025-09
Eli Lilly USD 14.53B 785M 2026-03
Incyte USD 115.62M 14.56M 2026-03
J&J USD 14.58B 392M 2026-03
Moderna USD 146M 7M 2026-03
Neurocrine Biosciences USD 64.5M 4.5M 2026-03
Pfizer USD 10.67B 13M 2026-03
PTC Therapeutics USD 75.57M 4.08M 2026-03
Sarepta Therapeutics USD 1B 86.37M 2026-03
Ultragenyx Pharmaceutical USD 55M 3M 2026-03
Vanda Pharmaceuticals USD 1.85M 190K 2025-12
Vertex Pharmaceuticals USD 1.77B 79.9M 2026-03